[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SK18932001A3 - Farmaceutický komplex - Google Patents

Farmaceutický komplex Download PDF

Info

Publication number
SK18932001A3
SK18932001A3 SK1893-2001A SK18932001A SK18932001A3 SK 18932001 A3 SK18932001 A3 SK 18932001A3 SK 18932001 A SK18932001 A SK 18932001A SK 18932001 A3 SK18932001 A3 SK 18932001A3
Authority
SK
Slovakia
Prior art keywords
composition
eletriptan
composition according
cyclodextrin
pharmaceutically acceptable
Prior art date
Application number
SK1893-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Anne Billotte
Original Assignee
Pfizer, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Inc. filed Critical Pfizer, Inc.
Publication of SK18932001A3 publication Critical patent/SK18932001A3/sk

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nanotechnology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SK1893-2001A 1999-06-29 2000-06-02 Farmaceutický komplex SK18932001A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex
PCT/IB2000/000746 WO2001000243A1 (fr) 1999-06-29 2000-06-02 Complexe pharmaceutique

Publications (1)

Publication Number Publication Date
SK18932001A3 true SK18932001A3 (sk) 2002-09-10

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1893-2001A SK18932001A3 (sk) 1999-06-29 2000-06-02 Farmaceutický komplex

Country Status (44)

Country Link
US (2) US6713461B1 (fr)
EP (1) EP1189640B1 (fr)
JP (2) JP4454900B2 (fr)
KR (1) KR20020015067A (fr)
CN (1) CN1198654C (fr)
AP (1) AP2001002369A0 (fr)
AR (1) AR033337A1 (fr)
AT (1) ATE290884T1 (fr)
AU (1) AU770169B2 (fr)
BG (1) BG106151A (fr)
BR (1) BR0011845A (fr)
CA (1) CA2376847C (fr)
CO (1) CO5170494A1 (fr)
CZ (1) CZ20014572A3 (fr)
DE (1) DE60018744T2 (fr)
DZ (1) DZ3320A1 (fr)
EA (1) EA003908B1 (fr)
EC (1) ECSP003551A (fr)
EE (1) EE200100697A (fr)
ES (1) ES2235879T3 (fr)
GB (1) GB9915231D0 (fr)
GE (1) GEP20043377B (fr)
GT (1) GT200000102A (fr)
HR (1) HRP20010951A2 (fr)
HU (1) HUP0201629A3 (fr)
IL (1) IL146341A0 (fr)
IS (1) IS6163A (fr)
MA (1) MA26801A1 (fr)
MX (1) MXPA01013274A (fr)
NO (1) NO20016430L (fr)
NZ (1) NZ515235A (fr)
OA (1) OA11964A (fr)
PA (1) PA8496801A1 (fr)
PE (1) PE20010346A1 (fr)
PL (1) PL352902A1 (fr)
SK (1) SK18932001A3 (fr)
SV (1) SV2002000112A (fr)
TN (1) TNSN00142A1 (fr)
TR (1) TR200103827T2 (fr)
UA (1) UA66932C2 (fr)
UY (1) UY26224A1 (fr)
WO (1) WO2001000243A1 (fr)
YU (1) YU87501A (fr)
ZA (1) ZA200110454B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
AU2003269965B2 (en) * 2002-08-20 2008-02-21 Otsuka Pharmaceutical Co., Ltd Aripiprazole complex formulation and method
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (fr) * 2016-01-15 2017-07-20 Cadila Healthcare Limited Composition intranasale comprenant des agonistes de récepteur 5ht1b/1d
US20190224171A1 (en) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Liquid rizatriptan compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
HU211648A9 (en) 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
BR9106978A (pt) 1990-10-15 1993-09-28 Pfizer Derivados de indol
ZA941544B (en) 1993-03-05 1994-10-31 Hexal Pharma Gmbh Crystalline cyclodextrin complexes of ranitidine hydrochloride, process for their preparation and pharmaceutical compositions containing the same.
EP0699079B1 (fr) 1994-03-07 2004-09-29 The Dow Chemical Company Conjugues dendrimeres bioactifs et/ou cibles comprenant du materiel genetique
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
BR9710289A (pt) 1996-07-11 1999-08-17 Farmarc Nederland Bv Composi-Æo farmac-utica contendo sal cido de adi-Æo de medicamento b sico
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
ES2163291T3 (es) 1997-07-03 2002-01-16 Pfizer Composiciones farmaceuticas que contienen eletriptan hemisulfato y cafeina.
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
AP2001002369A0 (en) 2001-12-31
YU87501A (sh) 2004-05-12
PL352902A1 (en) 2003-09-22
AU4774100A (en) 2001-01-31
CN1359303A (zh) 2002-07-17
MA26801A1 (fr) 2004-12-20
DE60018744T2 (de) 2006-05-18
BR0011845A (pt) 2002-03-05
GB9915231D0 (en) 1999-09-01
UA66932C2 (en) 2004-06-15
NO20016430L (no) 2002-02-26
HRP20010951A2 (en) 2005-04-30
CN1198654C (zh) 2005-04-27
SV2002000112A (es) 2002-02-05
GT200000102A (es) 2001-12-14
AR033337A1 (es) 2003-12-17
JP2003503364A (ja) 2003-01-28
EP1189640B1 (fr) 2005-03-16
EP1189640A1 (fr) 2002-03-27
PE20010346A1 (es) 2001-03-26
BG106151A (en) 2002-05-31
EA003908B1 (ru) 2003-10-30
IS6163A (is) 2001-11-16
IL146341A0 (en) 2002-07-25
CO5170494A1 (es) 2002-06-27
US6713461B1 (en) 2004-03-30
KR20020015067A (ko) 2002-02-27
CA2376847C (fr) 2007-09-25
ZA200110454B (en) 2002-12-20
CZ20014572A3 (cs) 2002-08-14
AU770169B2 (en) 2004-02-12
ES2235879T3 (es) 2005-07-16
JP2006257091A (ja) 2006-09-28
EE200100697A (et) 2003-02-17
EA200101106A1 (ru) 2002-06-27
NO20016430D0 (no) 2001-12-28
ECSP003551A (es) 2002-01-25
HUP0201629A2 (hu) 2003-03-28
US20040186076A1 (en) 2004-09-23
ATE290884T1 (de) 2005-04-15
DZ3320A1 (fr) 2001-01-04
HUP0201629A3 (en) 2003-11-28
DE60018744D1 (de) 2005-04-21
OA11964A (en) 2006-04-17
TR200103827T2 (tr) 2002-05-21
PA8496801A1 (es) 2002-02-21
MXPA01013274A (es) 2002-06-04
UY26224A1 (es) 2001-01-31
TNSN00142A1 (fr) 2005-11-10
CA2376847A1 (fr) 2001-01-04
JP4454900B2 (ja) 2010-04-21
WO2001000243A1 (fr) 2001-01-04
GEP20043377B (en) 2004-04-13
NZ515235A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
AU712546B2 (en) Inclusion complex containing indole selective serotonin agonist
US7202233B2 (en) Alprazolam inclusion complexes and pharmaceutical compositions thereof
JP2006257091A (ja) 医薬錯体
JP3518601B2 (ja) エバスタイムまたはその類似体に基づく医薬組成物
RU2400227C2 (ru) Состав, содержащий твердую дисперсию базедоксифен ацетата
EP1092431B1 (fr) Compositions contenant du lasofoxifène
AU659311B2 (en) The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
CZ2001357A3 (cs) Prevence recidivy migrény
KR20060134146A (ko) 선택적 에스트로겐 수용체 모듈레이터로서의 바제독시펜아스코르베이트
MXPA02008376A (es) Material cristalino.
JP2000072677A (ja) 抗真菌性組成物
JPS58116423A (ja) メタノプロスタサイクリン製剤組成物
JPH11508916A (ja) トリアゾリルメチル−インドールエチルアミン重硫酸塩
CN1225018A (zh) 含有吲哚选择性的5-羟色胺激动剂的包合配合物